Company Overview of Aerpio Therapeutics, Inc.
Aerpio Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of diabetic eye disease and inflammatory bowel disease. It offers tie-2 activators and HIF-1 stabilizers. The company was incorporated in 2011 and is based in Cincinnati, Ohio.
9987 Carver Road
Cincinnati, OH 45242
Founded in 2011
Key Executives for Aerpio Therapeutics, Inc.
Chief Executive Officer and Director
Chief Financial Officer and Vice President
Compensation as of Fiscal Year 2014.
Aerpio Therapeutics, Inc. Key Developments
Aerpio Therapeutics Announces Publication of Preclinical Data on AKB-9778 for Common Eye Diseases
Sep 2 14
Aerpio Therapeutics, Inc. announced the publication of preclinical data demonstrating that lead candidate, AKB-9778, reduces abnormal blood vessel growth and leakage in mouse models of ophthalmic diseases, such as diabetic macular edema (DME) and age-related macular degeneration. These data were published in collaboration with researchers at Johns Hopkins School of Medicine, Max Planck Institute, and Duke University in the September 2, 2014, issue of The Journal of Clinical Investigation. AKB-9778 is a small molecule activator of Tie2 currently in a Phase 2 clinical study for the treatment of DME. The results of the JCI study clearly demonstrate the potential benefit of restoring Tie2 activation in mouse models of major vision-robbing eye diseases. Importantly, the results support the benefit of AKB-9778 as either a monotherapy or as an adjunct to anti-VEGF agents.
Aerpio Therapeutics, Inc. Announces Full Results from Phase 1b/2a Study of AKB-9778 for the Treatment of Diabetic Macular Edema
May 5 14
Aerpio Therapeutics, Inc. announced the presentation of the full results of its Phase 1b/2a study of Tie2 activator, AKB-9778, for the treatment of diabetic macular edema (DME) at the Association for Research in Vision and Ophthalmology Annual Meeting (ARVO) in Orlando, FL. In the study, one month of daily AKB-9778 treatment was well-tolerated, produced clinically meaningful reduction in retinal thickness, with concomitant improvement in visual acuity, in some of the patients. Tie2 plays a central role in maintaining vascular integrity, which prevents vascular leak seen in conditions such as DME. AKB-9778 activates Tie2 by inhibiting the natural brake of Tie2, human protein tyrosine phosphatase (HPTP). This is the first study to show that activation of Tie2 can have a beneficial effect in patients with DME.
Aerpio Therapeutics, Inc. Presents at 13th Annual Needham Healthcare Conference, Apr-09-2014 09:20 AM
Apr 1 14
Aerpio Therapeutics, Inc. Presents at 13th Annual Needham Healthcare Conference, Apr-09-2014 09:20 AM. Venue: The Westin Grand Central Hotel, New York, New York, United States. Speakers: Joseph H. Gardner, Chief Executive Officer and Director.
Similar Private Companies By Industry
Recent Private Companies Transactions
April 22, 2014